caa a22 4500 397563264 CHVBK 20180308164821.0 cr unu---uuuuu 161202e19961120xx s 000 0 eng 10.1093/jnci/88.22.1635 doi (NATIONALLICENCE)oxford-10.1093/jnci/88.22.1635 Rosenberg Steven A. Surgery Branch, Division of Clinical Sciences, National Cancer Institute Bethesda, MD Development of Cancer Immunotherapies Based on Identification of the Genes Encoding Cancer Regression Antigens [Elektronische Daten] [Steven A. Rosenberg] Tumor-infiltrating lymphocytes (TILs) have been grown from patients with metastatic melanoma and administered to the autologous patients to identify those TIL populations capable of mediating tumor regression. These TILs have been used to clone the genes that encode melanoma antigens. With the use of this strategy, we have identified six different genes encoding antigens restricted by multiple HLA alleles that appear to be related to tumor regression in patients. These antigens are now being used to develop immunization approaches for the treatment of patients with metastatic melanoma. The availability of genes encoding unique cancer antigens is opening new possibilities for the development of immunotherapies for the treatment of patients with cancer. © Oxford University Press REVIEWS nationallicence JNCI: Journal of the National Cancer Institute Oxford University Press 88/22(1996-11-20), 1635-1644 0027-8874 88:22<1635 1996 88 jnci https://doi.org/10.1093/jnci/88.22.1635 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jnci/88.22.1635 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Rosenberg Steven A. Surgery Branch, Division of Clinical Sciences, National Cancer Institute Bethesda, MD NATIONALLICENCE 773 0- JNCI: Journal of the National Cancer Institute Oxford University Press 88/22(1996-11-20), 1635-1644 0027-8874 88:22<1635 1996 88 jnci Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford